tbuckley/cabot-search huggingface dataset:
Abstract IA14: Breast cancer evolution – Insights from single cell genomics
Authors: Nicholas E. Navin
Journal: Cancer Research (2020)

Abstract In this talk I will discuss our efforts to develop and apply single cell genome sequencing methods to study premalignant breast cancer invasion, as well as our efforts to build an atlas of normal cell types in human breast tissues. To study invasion in 10 patients with ductal carcinomas in situ (DCIS) premalignancies we developed a Topographic Single Cell Sequencing (TSCS) method that has spatial resolution to measure genomic copy number profiles in patients with synchronous DCIS-IDC tissues. Our data revealed a multi-clonal invasion model, in which genome evolution occurred within the ducts leading to the generation of multiple clones that co-migrated across the basement membrane to establish the invasive carcinomas. Our group is leading a collaborative effort to establish a human breast atlas of normal tissues using single cell RNA sequencing of 30 women. These data have identified major cell types including epithelial cells (luminal HR+, luminal secretory, basal), fibroblasts, adipocytes and endothelial cells (vascular, lymphatic) as well as immune cells (lymphocytes, myeloid). For each cell type, we have identified multiple (2-5) expression states that correspond to different biological functions. Collectively these data provide a ‘human genome’ reference of normal cell types and cell states in the human breast tissues to understand how the stromal and immune microenvironment is reprogrammed in breast cancers. Citation Format: Nicholas E. Navin. Breast cancer evolution – Insights from single cell genomics [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA14.
Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis
Authors: Jayasree Krishnan, Victoria Nachar, Bernard Lawrence Marini, Anthony J. Perissinotti, Tycel J. Phillips, Mark S Kaminski, Shannon A. Carty, Ryan A. Wilcox
Journal: Blood (2020)
Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA
Authors: Tracy Murphy, Stanley W.K. Ng, Ian King, Tong Zhang, Andrea Arruda, Narmin Ibrahimova, Jaime O. Claudio, Fiona Ferrera, Kristele Pan, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, Vikas Gupta, Dawn Maze, Caroline J McNamara, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen W.L. Yee, Dina Khalaf, Brian Leber, Mitchell Sabloff, Anne Tierens, Mark D. Minden, Tracy L. Stockley, Steven M Chan, Jean C.Y. Wang
Journal: Blood (2020)
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations
Authors: Bernhard Kratzer, Doris Trapin, Paul Ettel, Ulrike Körmöczi, Arno Rottal, Friedrich Tuppy, Melanie Feichter, Pia Gattinger, Kristina Borochova, Yulia Dorofeeva, Inna Tulaeva, Milena Weber, Katharina Grabmeier‐Pfistershammer, Peter A. Tauber, Marika Gerdov, Bernhard Mühl, Thomas Perkmann, Ingrid Fae, Sabine Wenda, Harald Führer, Rainer Henning, Rudolf Valenta, Winfried F. Pickl
Journal: Allergy (2020)

Abstract Background SARS‐CoV‐2 has triggered a pandemic that is now claiming many lives. Several studies have investigated cellular immune responses in COVID‐19‐infected patients during disease but little is known regarding a possible protracted impact of COVID‐19 on the adaptive and innate immune system in COVID‐19 convalescent patients. Methods We used multiparametric flow cytometry to analyze whole peripheral blood samples and determined SARS‐CoV‐2‐specific antibody levels against the S‐protein, its RBD‐subunit, and viral nucleocapsid in a cohort of COVID‐19 convalescent patients who had mild disease ~10 weeks after infection (n = 109) and healthy control subjects (n = 98). Furthermore, we correlated immunological changes with clinical and demographic parameters. Results Even ten weeks after disease COVID‐19 convalescent patients had fewer neutrophils, while their cytotoxic CD8 + T cells were activated, reflected as higher HLA‐DR and CD38 expression. Multiparametric regression analyses showed that in COVID‐19‐infected patients both CD3 + CD4 + and CD3 + CD8 + effector memory cells were higher, while CD25 + Foxp3 + T regulatory cells were lower. In addition, both transitional B cell and plasmablast levels were significantly elevated in COVID‐19‐infected patients. Fever (duration, level) correlated with numbers of central memory CD4 + T cells and anti‐S and anti‐RBD, but not anti‐NC antibody levels. Moreover, a “young immunological age” as determined by numbers of CD3 + CD45RA + CD62L + CD31 + recent thymic emigrants was associated with a loss of sense of taste and/or smell. Conclusion Acute SARS‐CoV‐2 infection leaves protracted beneficial (ie, activation of T cells) and potentially harmful (ie, reduction of neutrophils) imprints in the cellular immune system in addition to induction of specific antibody responses.
Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with <i>TP53</i>-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Authors: Meghan C. Thompson, Matthew S. Davids, Nitin Jain, Jacob D. Soumerai, Praveen Ramakrishnan Geethakumari, Amy Gubits, Denice Hickman, Anders Wennborg, Eyal C. Attar, Omar Abdel-Wahab, Anthony R. Mato
Journal: Blood (2020)
Screening Donor Samples Using Multicolor Flow Cytometry Prior to Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Disease Monitoring Post-Transplantation
Authors: Hui Wang, Aixian Wang, Meiwei Gong, Junyi Zhen, Xueying Wu, Man Chen, Qing Du, Peihua Lu
Journal: Blood (2020)
A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
Authors: Xian Zhang, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu
Journal: Blood (2020)
Analytical Performance of Modified Anti-FXa Assays for Andexanet Alfa-Containing Plasma Samples on the ACL TOP/TOP 50 Coagulation Analyzers
Authors: Anuja Khan, Krisjela Shishko, Ryan Marett, Sam Arcidiacono, Vy Nguyen, Genmin Lu, Khanh Bui, Pamela B. Conley, Anne Winkler
Journal: Blood (2020)
Mitochondrial Fate of Regenerative Hematopoietic Stem Cells Is Sequentially Controlled By Two Specific Conformations of Connexin-43
Authors: Abhishek K Singh, Ashley M Wellendorf, Breanna Bohan, Daniel Gonzalez-Nieto, Luis C Barrio, Ashwini S. Hinge, Marie-Dominique Filippi, Jose A. Cancelas
Journal: Blood (2020)
Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia
Authors: Ana Rio-Machin, Pedro Casado-Izquierdo, Juho Miettinen, Findlay Bewicke-Copley, Naeem Khan, Jonas Demeulemeester, Szilvia Krizsán, Jiexin Zheng, Christopher Middleton, Wencheng Yin, William Grey, Farideh Miraki-Moud, Janet Matthews, Marianne Grantham, Kevin Rouault-Pierre, Krister Wennerberg, Alun Parsons, Hannah Armes, Karina EM Close, Doriana Di Bella, James Cavenagh, Sylvie D Freeman, Peter Van Loo, Csaba Bödör, Kimmo Porkka, Caroline A Heckman, Jun Wang, David Taussig, Dominique Bonnet, Jean-Baptiste Cazier, Pedro Cutillas, Jude Fitzgibbon
Journal: Blood (2020)
Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation
Authors: Donald T. Gracias, Gurupreet S. Sethi, Amit K. Mehta, Haruka Miki, Rinkesh K. Gupta, Hideo Yagita, Michael Croft
Journal: Journal of Allergy and Clinical Immunology (2020)
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study
Authors: Frédéric Millot, Meinolf Suttorp, Stéphanie Ragot, Guy Leverger, Jean-Hugues Dalle, Birgitta Versluijs, Birgitte Lausen, Marina Borisevich
Journal: Blood (2020)
A Novel Aryl-Guanidinium Based Compound Targets the STAT3 Signalling Pathway, Downregulates MCL-1 Expression and Induces Anti-Myeloma Activity
Authors: Rebecca Amet, Viola Previtali, Helene Mihigo, Emily Sheridan, Sarah Brophy, Patrick J Hayden, Paul V Browne, Isabel Rozas, Daniela Zisterer, Tony M McElligott
Journal: Blood (2020)
An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Authors: Sebastian Grosicki, Genadi Iosava, Mamia Zodelava, Nikolay Tzvetkov, Tadeusz Robak, Atanas Radinoff, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair
Journal: Blood (2020)
Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome
Authors: Alyssa L. Kennedy, Kasiani C. Myers, James Bowman, Christopher J. Gibson, Gwen M. Muscato, Robert Klein, Kaitlyn Ballotti, Nicholas Camarda, Elissa M. Furutani, Chad E. Harris, Shanshan Liu, Ashley Galvin, Maggie Malsch, David C. Dale, John M Gansner, Taizo A. Nakano, Alison A. Bertuch, Adrianna Vlachos, Jeff H. Lipton, Paul Castillo, James Connelly, John Edwards, Nobuko Hijiya, Richard Ho, Inga Hofmann, James N Huang, Sioban B. Keel, Adam J. Lamble, Bonnie W Lau, Kelly J. Walkovich, Maxim Norkin, Wendy Stock, Steffen Boettcher, Christian Brendel, Elliot Stieglitz, Mark D. Fleming, Stella M. Davies, Edie A. Weller, Chris Bahl, Scott L. Carter, Akiko Shimamura, R. Coleman Lindsley
Journal: Blood (2020)
<i>CREB3L1</i> Overexpression Can Reliably Discriminate Ph-MPNs from Reactive Cases
Authors: Soji Morishita, Hajime Yasuda, Saya Yamawaki, Hideya Kawaji, Masayoshi Itoh, Yoko Edahiro, Misa Imai, Yasushi Kogo, Satoshi Tsuneda, Akimichi Ohsaka, Yoshihide Hayashizaki, Marito Araki, Norio Komatsu
Journal: Blood (2020)
Abstract 535: Mathematical Modeling of Hyperpolarized Pyruvate Metabolism in Human Heart
Authors: Katarina Yaros, Jae Mo Park, Craig Malloy, Jeffry Alger, Tarique Hussain, Vlad G Zaha
Journal: Circulation Research (2020)

Background: Dissolution dynamic nuclear polarization is a novel method that increases more than 10,000-fold the 13 C signal-to-noise ratio and emerges as a useful tool for detection of molecules much less prevalent than water in the human body. Hyperpolarized [1- 13 C] pyruvate (HP) permits the noninvasive, nonradioactive study of metabolic flux via pyruvate dehydrogenase, a key enzyme in the complex cardiac adaptation to physical activity, energy sources, and in various disease states. The aim of this study is to define an analysis pipeline of multiparametric, non-steady-state, real-time human cardiac magnetic resonance spectroscopic investigations. Methods: HP was infused intravenously into five human subjects. Dynamic spectroscopic data was acquired for [1- 13 C]- pyruvate, 13 C-alanine, [1- 13 C]-lactate, and 13 C-bicarbonate at two consecutive times for each subject. Imaging data were exported into MATLAB. We employed a first-order kinetic model to fit the signal for the hyperpolarized metabolites assuming bidirectional flow between pyruvate and lactate as well as pyruvate and alanine. A gamma variate input function was used to model the initial pyruvate bolus. We also calculated non-parametric values to describe the signal for each metabolite, specifically area-under-curve (AUC) and time-to-peak (TTP). The repeatability analysis was performed using an ANOVA-based method. Results: Rate constants derived from the kinetic model: kPL 0.016 ± 0.008s -1 , kPA 0.012 ± 0.006s -1 , kPB 0.024±0.0095s -1 are of similar order of magnitude to prior studies. The reverse constant for lactate to pyruvate conversion (kLP) is relatively unchanged across the subjects (0.0099±0.0005), and reverse constant for alanine to pyruvate (kAP) conversion is almost negligible (0.0008 ± 0.0012). The model well describes the metabolites signal over time. Within subject repeatability was higher for TTP (lactate: 0.981 ± 0.018) ) than for rate constants (kPL 0.823 ± 0.153) and AUC (lactate 0.697 ± 0.244) with kPB having the lowest repeatability (0.325 ± 0.424) due to a single outlier. Conclusions: We present a real-time pipeline for analysis and modelling of pyruvate metabolism in the human heart and confirm that it is reproducible within the same subject under same conditions.
Reduction in Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Ameet Patel, Karina L Wilkerson, Kathryn A. Culos, Jennifer Green, Michael T. Byrne, Salyka M. Sengsayadeth, Bhagirathbhai Dholaria, Bipin N. Savani, Stacey Ann Goodman, Wichai Chinratanalab, Reena Jayani, Katie S. Gatwood, Brian G. Engelhardt, Adetola A. Kassim
Journal: Blood (2020)
Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19
Authors: Spyridoula Vasileiou, Manik Kuvalekar, Aster Workineh, Ayumi Watanabe, Yovana Velazquez, Suhasini Lulla, Helen E. Heslop, Kimberly Mooney, Kevin Grimes, George Carrum, LaQuisa C. Hill, Premal Lulla, Ann M. Leen
Journal: Blood (2020)
Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients
Authors: Thomas G. Knight, Melissa Aguiar, Myra Robinson, Allison Martin, Heather Cranford, Tommy Chen, Rupali Bose, Jing Ai, Brittany K. Ragon, Aleksander L. Chojecki, Nilay A. Shah, Srinivasa R. Sanikommu, James Symanowski, Edward A Copelan, Michael R. Grunwald
Journal: Blood (2020)
Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML
Authors: Bing Z Carter, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, Xuan Zhang, Yuki Nishida, Steven M. Kornblau, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff
Journal: Blood (2020)
Abstract 425: Protein Kinase Activity of Pi3kγ Regulates Insulin-βArs Cross-talk
Authors: Anita SAHU, Sromona Mukherjee, Kate Stenson, Maradumane L Mohan, Sathyamangla V Prasad
Journal: Circulation Research (2020)

β adrenergic receptor (βAR) function is regulated by G-protein coupled receptor (GPCR) kinase (GRK) driven desensitization and protein phosphatase 2A (PP2A) mediated resensitization to its classical agonist. Surprisingly, Insulin modulates (βARs) function thus regulating cardiac function. Although insulin is known to modulate βAR function through GRKs, less is known about insulin mediated resensitization mechanisms. PI3Kγ is activated by GPCRs regulates resensitization by inhibiting PP2A activity. Therefore, we tested whether insulin could mediate βAR dysfunction through inhibition of resensitization. Co-immunoprecipitation in cardiac lysates and surface plasmon resonance (SPR) with purified proteins show that PI3Kγ interacts with GRK-2 resulting in recruitment of GRK2-PI3Kγ to the β2AR complex upon insulin. Furthermore, use of PI3K inhibitors significantly reduced Insulin-stimulated β2ARs phosphorylation in HEK293 cells. The role of PI3Kγ was further validated by the loss of insulin stimulated β 2 AR phosphorylation in PI3Kγ-knockout (KO) mouse embryonic fibroblasts (MEFs), shRNA and CRIPSR knockdown of PI3Kγ. Data shows that PI3Kγ inhibits PP2A activity at the βAR complex upon insulin while loss of PI3Kγ unravels this inhibition resulting in increased PP2A activity leading to β2AR dephosphorylation and resensitization. Mechanistically, PI3Kγ inhibits PP2A activity at the β2AR complex by phosphorylating an endogenous inhibitor of PP2A (I2PP2A). CRISPR knockout and siRNA knockdown of endogenous I2PP2A in HEK293 cells restored PP2A activity resulting in β2AR dephosphorylation despite PI3Kγ. Furthermore, β blocker (propranolol) pretreatment did not affect β2AR phosphorylation and there was no β-arrestin recruitment to the βAR complex with Insulin. Together these studies show that Insulin mediates β2AR desensitization through β-agonist and β-arrestin independent mechanisms wherein, PI3Kγ-mediated regulation of PP2A activity plays a pivotal role in cardiac βAR function in hyperinsulemic conditions like diabetes and obesity.
Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study
Authors: Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Sosana Delimpasi, Michele Cavo, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Gavriatopoulou, Maria Roussou, Despina Fotiou, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Meletios A Dimopoulos
Journal: Blood (2020)
Initial Treatment Vs Watch and Wait in Advanced-Stage Follicular Lymphoma in the Rituximab Era - an Analysis of the National Cancer Database (NCDB)
Authors: Ning Dong, Hayder Saeed, Leidy Isenalumhe, Franco Castillo Tokumori, Bijal Shah, Sameh Gaballa, Celeste Bello, Lubomir Sokol, Javier Pinilla Ibarz, Julio C. Chavez
Journal: Blood (2020)
Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT
Authors: Firoozeh Sahebi, Dirk-Jan Eikema, Linda Koster, Nicolaus Kröger, Ellen Meijer, Goda Choi, Montserrat Rovira, Yener Koc, Emanuele Angelucci, Didier Blaise, Corrado Tarella, Andrew McDonald, Concepcion Herrera Arroyo, Noel Milpied, Luca Castagna, Friedrich Stoelzel, Jaime Sanz Caballer, Johanna Tischer, Fabio Ciceri, David Valcarcel, Luigi Rigacci, Patrick J Hayden, Meral Beksac, Ibrahim Yakoub-Agha, Stefan Schonland
Journal: Blood (2020)
CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial
Authors: Andrew Wei, Gail J. Roboz, Hervé Dombret, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, Christopher Pocock, Dominik Selleslag, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Farhad Ravandi
Journal: Blood (2020)
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II–III Breast Cancer: A Multicenter Value Analysis
Authors: Colby J. Hyland, Flora Varghese, Christina Yau, Heather Beckwith, Katia Khoury, William Varnado, Gillian L. Hirst, Robert R. Flavell, A. Jo Chien, Douglas Yee, Claudine J. Isaacs, Andres Forero-Torres, Laura J. Esserman, Michelle E. Melisko
Journal: Journal of the National Comprehensive Cancer Network (2020)

Background: Metastatic staging imaging is not recommended for asymptomatic patients with stage I–II breast cancer. Greater distant metastatic disease risk may warrant baseline imaging in patients with stage II–III with high-risk biologic subtypes. NCCN Guidelines recommend considering CT of the chest, abdomen, and pelvis (CT CAP) and bone scan in appropriate patients. CT CAP and bone scan are considered standard of care (SoC), although PET/CT is a patient-centered alternative. Methods: Data were available for 799 high-risk patients with clinical stage II–III disease who initiated screening for the I-SPY2 trial at 4 institutions. A total of 564 complete records were reviewed to compare PET/CT versus SoC. Costs were determined from the payer perspective using the national 2018 Medicare Physician Fee Schedule and representative reimbursements to the University of California, San Francisco (UCSF). Incremental cost-effectiveness ratio (ICER) measured cost of using PET/CT per percent of patients who avoided a false-positive (FP). Results: The de novo metastatic disease rate was 4.6%. Imaging varied across the 4 institutions ( P &lt;.0001). The FP rate was higher using SoC versus PET/CT (22.1% vs 11.1%; P =.0009). Mean time between incidental finding on baseline imaging to FP determination was 10.8 days. Mean time from diagnosis to chemotherapy initiation was 44.3 days with SoC versus 37.5 days with PET/CT ( P =.0001). Mean cost per patient was $1,132 (SoC) versus $1,477 (PET/CT) using the Medicare Physician Fee Schedule, with an ICER of $31. Using representative reimbursements to UCSF, mean cost per patient was $1,236 (SoC) versus $1,073 (PET/CT) for Medicare, and $3,083 (SoC) versus $1,656 (PET/CT) for a private payer, with ICERs of −$15 and −$130, respectively. Conclusions: Considerable variation exists in metastatic staging practices. PET/CT reduced FP risk by half and decreased workup of incidental findings, allowing for earlier treatment start. PET/CT may be cost-effective, and at one institution was shown to be cost-saving. Better alignment is needed between hospital pricing strategies and payer coverage policies to deliver high-value care.
Dependence on Schwann Cell-Derived Laminin-γ1 Differentiates Early Lymphoid and Myeloid Development
Authors: Kristin Komnick, Jennifer May, Pouneh Kermani, Sreemanti Basu, Irene Hernandez, Mark Zogg, British L Fields, Joshua Morris, Hartmut Weiler, Karen-Sue Carlson
Journal: Blood (2020)
Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents
Authors: Anne Sophie Kubasch, Pierre Peterlin, Thomas Cluzeau, Katharina S. Götze, Katja Sockel, Raphael Teipel, Madlen Jentzsch, Sabine Kayser, Habiba Attalah, Fatiha Chermat, Silke Gloaguen, Katja Jersemann, Dorothea Schipp, Aristoteles Giagounidis, Stuart McPherson, Irene Tirado-González, Arjan van de Loosdrecht, Pierre Fenaux, Uwe Platzbecker, Hind Medyouf, Lionel Ades
Journal: Blood (2020)
Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Myeloid Leukemia (AML)
Authors: Veronica A Guerra, Yasmin Alwash, Yan Yuanqing, Jorge M. Ramos Perez, Guillaume Richard-Carpentier, Ahmad S Alotaibi, Hycienth O Ahaneku, Bachar Samra, Arrvind Raghunath, Guillermo Montalban-Bravo, Naveen Pemmaraju, Courtney D. DiNardo, Naval Daver, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Tapan M. Kadia
Journal: Blood (2020)
BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
Authors: Piers Blombery, Ella R Thompson, Xiangting Chen, Tamia Nguyen, Mary Ann Anderson, David Alan Westerman, John F. Seymour, Constantine S. Tam, Michael A Dengler, David C.S. Huang, Andrew Wei, Andrew W Roberts
Journal: Blood (2020)